Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-25-0243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Marta Laganà und 12 weiteren Autor:innen. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Intestinal Neoplasms, Stomach Neoplasms. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Neuroendocrine neoplasms (NENs) are rare tumors with increasing incidence. Data on the prognosis of NEN patients in the real-world setting are limited. We aim to explore survival predictors and the impact of novel treatments in a cohort of patients with NENs from various primary sites. This was a retrospective study of subjects diagnosed with gastroenteropancreatic (GEP) or thoracic NENs and referred to a single institution over more than a decade (2010–2023). The primary objective was to describe the overall survival (OS) and progression-free survival (PFS) of patients with advanced-stage disease undergoing first, second, and third-line therapy. The secondary objectives were to identify predictors of OS and PFS. We included 239 NEN patients. Systemic antineoplastic therapies were administered to 149 subjects (62.3%). In patients treated only with first-line therapy, the OS rate was 75 and 74% at 12 and 18 months, respectively. We observed significant univariable associations between Ki-67 index, primary tumor site, morphology, clinical stage, and OS. The multivariable analysis confirmed a significant association between Ki-67 index, clinical stage, and OS. In patients undergoing second-line therapy, the OS rate was 72 and 61% at 12 and 18 months, respectively, and the Ki-67 index was again associated with OS in the multivariable analysis. GEP NEN patients who received 177 Lu-Dotatate showed a numerically higher OS rate at 24 months compared to those who did not receive radioligand therapy. In this real-world study of patients with NENs, we confirmed Ki-67 as a strong prognostic parameter and suggested that 177 Lu-Dotatate has the potential to prolong OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
ORCID-Profile: Vito Amoroso
Zitieren
APA
Laganà, M., Gallo, F., Salvetti, M., Smussi, D., Esposito, A., Carola, G., Carpani, M., Morocutti, F., Cosentini, D., Pedersini, R., Grisanti, S., Berruti, A., & Amoroso, V. (2025). Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0243
Vancouver
Laganà M, Gallo F, Salvetti M, Smussi D, Esposito A, Carola G, et al. Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0243
BibTeX
@article{Lagan2025,
author = {Laganà, Marta and Gallo, Fabio and Salvetti, Maddalena and Smussi, Davide and Esposito, Andrea and Carola, Giorgia and Carpani, Matteo and Morocutti, Filippo and Cosentini, Deborah and Pedersini, Rebecca and Grisanti, Salvatore and Berruti, Alfredo and Amoroso, Vito},
title = {Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-25-0243}
}
EUVIMED